Hepatic epithelioid hemangioendothelioma successfully treated with living donor liver transplantation: A case report and literature review

Fukuhara, Sotaro; Tahara, Hiroyuki; Hirata, Yoshito; Ono, Kosuke; Hamaoka, Michinori; Shimizu, Seiichi; Hashimoto, Shinji; Kuroda, Satoshi; Ohira, Masaichi; Ide, Kentaro; Kobayashi, Tsuyoshi; Ohdan, Hideki

doi:10.1002/ccr3.2558

Cited by 8 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is believed that successful hepatectomy or LT promotes long-term survival even in the presence of distal metastasis[ 55 ]. According to Fukuhara et al[ 56 ], it may be better to perform adjuvant therapy after LT in some aggressive cases and he claims that mTOR inhibitors are effective in preventing the recurrence and improving the survival rate after LT for hepatocellular carcinoma especially when the risk of recurrence was high. Ablation therapy also has a good effect on single and small HEHE, especially for marginal patients with malignant tumors[ 57 ].…”

Section: Therapymentioning

confidence: 99%

“…It was reported that the combination of the anti-VEGF drug bevacizumab and cell cycle inhibitor capecitabine achieved a good curative effect[ 19 , 61 ]. Other drugs such as mTOR inhibitors[ 56 ], thalidomide[ 62 - 64 ], pegylated liposomal doxorubicin[ 65 ], metronomic cyclophosphaide[ 66 ] and others have been introduced for the treatment of EHE and have acquired good results. For patients treated with pazopanib, Bally et al[ 60 ] proposed that the intratumoral changes observed on follow-up CT, such as a change in tumor density without obvious tumor contraction or calcification, can be regarded a strong indication of tumor response[ 60 ].…”

Section: Therapymentioning

confidence: 99%

See 1 more Smart Citation

Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy

Kou

Chen

Zhou

et al. 2020

WJCC

View full text Add to dashboard Cite

With an estimated incidence of only 1-2 cases in every 1 million people, hepatic epithelioid hemangioendothelioma (HEHE) is a rare vascular endothelial cell tumor occurring in the liver and consisting of epithelioid and histiocyte-like vascular endothelial cells in mucus or a fibrotic matrix. HEHE is characterized as a low-to-moderate grade malignant tumor and is classified into three types: solitary, multiple, and diffuse. Both the etiology and characteristic clinical manifestations of HEHE are unclear. However, HEHE has a characteristic appearance on imaging including ultrasound, magnetic resonance imaging, and positron emission tomography/computerized tomography. Still, its diagnosis depends mainly on pathological findings, with immunohistochemical detection of endothelial markers cluster of differentiation 31 (CD31), CD34, CD10, vimentin, and factor VIII antigen as the basis of diagnosis. Hepatectomy and/or liver transplantation are the first choice for treatment, but various chemotherapeutic drugs are reportedly effective, providing a promising treatment option. In this review, we summarize the literature related to the diagnosis and treatment of HEHE, which provides future perspectives for the clinical management of HEHE.

show abstract

Section: Therapymentioning

confidence: 99%

Section: Therapymentioning

confidence: 99%

Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy

Kou

Chen

Zhou

et al. 2020

WJCC

View full text Add to dashboard Cite

show abstract

“…Due to inadequate numbers for statistical analysis, the efficacy of LTx in terms of mean survival rate remained uncertain. However, in selected cases, living donor LTx has been shown to be effective [28]. Despite some success in HEHE with LTX, Lau ¨ffer et al study revealed a 5-year survival rate of 55.5% in HEHE patients regardless of treatment, thus further casting doubt on the necessity of LTx [29].…”

Section: Discussionmentioning

confidence: 99%

Irreversible Electroporation as a Valid Treatment Option for Hepatic Epithelioid Hemangioendothelioma: An International Multicenter Experience

Narayanan,

Spano,

Gentile

et al. 2024

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Purpose Hepatic epithelioid hemangioendothelioma (HEHE) is a rare tumor with currently no established standard of care. This international multicenter retrospective study assesses the use of percutaneous irreversible electroporation (IRE) as an ablative tool to treat HEHE and provides a clinical overview of the current management and role of IRE in HEHE treatment. Material and Methods Between 2017 and 2023, 14 patients with 47 HEHE tumors were treated with percutaneous IRE using CT-scan guidance in 23 procedures. Baseline patient and tumor characteristics were evaluated. Primary outcome measures included safety and effectiveness, analyzed using Common Terminology Criteria for Adverse Events (CTCAE) and treatment response by mRECIST criteria. Secondary outcome measures included technical success, post-treatment tumor sizes and length of hospital stay. Technical success was defined as complete ablation with an adequate ablative margin (intentional tumor free ablation margin > 5 mm). Results IRE treatment resulted in technical success in all tumors. Following a median follow-up of 15 months, 30 tumors demonstrated a complete response according to mRECIST criteria. The average tumor size pre-treatment was 25.8 mm, accompanied by an average reduction in tumor size by 7.5 mm. In 38 out of 47 tumors, there was no evidence of local recurrence. In nine tumors, residual tumor was present. There were no cases of progressive disease. Median length of hospital stay was one day. Only one grade 3 CTCAE event occurred, a pneumothorax requiring chest tube placement. Conclusion The current study provides evidence that IRE is a safe and efficacious minimally invasive treatment option for HEHE. Graphical Abstract

show abstract

“…[46][47][48][49][50][51] Recientemente se ha ensayado olaratumab más doxorrubicina en HEE hepático metastásico logrando una enfermedad estable. 52 Finalmente, Fukuhara et al 53 reportan un HEE hepático agresivo que ha sido tratado con trasplante hepático de forma exitosa.…”

Section: Discussionunclassified

Hemangioendotelioma cardiaco primario recurrente: reporte de caso y revisión de la literatura

Rosero¹,

Martínez²,

Gutiérrez³

et al. 2023

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

El hemangioendotelioma epitelioide (HEE) es un tumor maligno posiblemente de origen vascular. Su localización usual es los tejidos blandos, mediastino, sistema nervioso central, pleura, pulmones, hígado y hueso. Sin embargo, es extremadamente rara su aparición en el corazón. Se presenta el caso de un paciente masculino de 67 años de edad, quien consulta por disnea progresiva, edema de miembros inferiores y hepatomegalia congestiva dolorosa. Se diagnóstica mediante biopsia HEE cardiaco primario. Posteriormente, se documenta recidiva tumoral, razón por la que fue evaluado por la junta médica de tumores que decidió iniciar quimioterapia (paclitaxel más doxorrubicina liposomal durante 6 ciclos). El paciente continúa en seguimiento por oncología con evidencia de enfermedad estable. El HEE cardiaco es un tumor muy raro. El tratamiento con paclitaxel más doxorrubicina es un esquema de quimioterapia que puede ser considerado en el manejo del HEE cardíaco primario avanzado o recurrente después de la cirugía cardíaca.

show abstract

Hepatic epithelioid hemangioendothelioma successfully treated with living donor liver transplantation: A case report and literature review

Cited by 8 publications

References 36 publications

Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy

Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy

Irreversible Electroporation as a Valid Treatment Option for Hepatic Epithelioid Hemangioendothelioma: An International Multicenter Experience

Hemangioendotelioma cardiaco primario recurrente: reporte de caso y revisión de la literatura

Contact Info

Product

Resources

About